OncoMatch/Clinical Trials/NCT04448522
Reduced vs Conventional Dosage Intensity-modulated Radiotherapy for Chemotherapy-sensitive Stage II-III Nasopharyngeal Carcinoma
Is NCT04448522 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies non-drug interventions for nasopharyngeal carcinoma.
Through multicenter, open-label, randomised clinical trials, we intend to demonstrate that radiotherapy with reduced dose could significantly reduce the incidence of radiotherapy toxicities, improve the quality of life of patients while ensuring the tumor control rates for NPC patients staged as II-III who are sensitive to induction chemotherapy (imaging evaluation of CR/PR and EBV DNA copy number decreased to 0 copies/mL after induction chemotherapy)
Check if I qualifyExtracted eligibility criteria
Cancer type
Head and Neck Squamous Cell Carcinoma
Biomarker criteria
Required: EBV DNA undetectable (0 copies/mL after 3 cycles of GP induction chemotherapy)
EBV DNA copy number decreased to 0 copies/mL after 3 cycles of GP induction chemotherapy
Disease stage
Required: Stage T1-3N1-2M0, T2-3N0M0, STAGE II-III (8th AJCC edition)
Excluded: Stage IV
Staged as T1-3N1-2M0, T2-3N0M0 (stage II-III) at diagnosis (according to the 8th AJCC edition)
Prior therapy
Must have received: GP induction chemotherapy — induction
Evaluated as PR or CR after 3 cycles of GP induction chemotherapy
Cannot have received: chemotherapy or surgery
Exception: except diagnostic purpose
Primary and regional lesions have been treated with chemotherapy or surgery (except diagnostic purpose)
Lab requirements
Blood counts
normal bone marrow function
Kidney function
creatinine clearance rate of at least 60 ml/min or creatinine of no more than 1.5 times the upper normal limit
Liver function
total bilirubin, ast and alt levels of no more than 2.5 times the upper normal limit
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify